Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Diseases and Conditions Researched

Pulmonary Fibrosis

What is the purpose of this trial?

The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF).


Participation Guidelines

Age: 40 Years - 90 Years
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Bristol-Myers Squibb Company
Dates:
Last Updated:
Study HIC#: 1308012484